AI scan analysis points to a broader lung effect for Endeavor's taladegib

An artificial intelligence reading of lung scans from a mid-stage trial of Endeavor BioMedicines' taladegib has found that the experimental drug improved the physical structure of the lungs in idiopathic pulmonary fibrosis (IPF), an effect its developers argue standard breathing tests capture only in part.

The analysis was carried out by Brainomix, a UK medtech company spun out of the University of Oxford in 2010 that builds AI imaging tools for stroke and lung disease, using its Brainomix 360 e-Lung software. Findings were presented at the European Respiratory Society congress in Barcelona on Tuesday as a late-breaking abstract.